AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for ...

Bavarian Nordic said on Thursday it has signed an agreement with the United Nations Children's Fund (UNICEF) for one million ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of p14,100.00. Eric Le Berrigaud has given ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care providers similar to other flu shots. Now the vaccinemaker has approval to ...